Investigating how reduced adenylyl cyclase type 5 may protect against Alzheimer's disease.
Alzheimer’s Disease Protection by Reduced Adenylyl Cyclase Type 5
This study is looking at how a protein called AC5 affects Alzheimer's disease and whether reducing it can help improve health and protect against problems related to the disease, using a special mouse model to see if it leads to better metabolism, exercise, and overall brain health, which could help find new ways to prevent memory loss in people.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-10526756 on NIH RePORTER |
What this research studies
This research explores the role of adenylyl cyclase type 5 (AC5) in Alzheimer's disease (AD) by examining how its reduction can lead to healthful longevity and protection against metabolic dysfunctions associated with AD. The study utilizes a specific mouse model that lacks AC5 to assess improvements in metabolism, exercise capacity, and resistance to oxidative stress, all of which are critical factors in the development of AD. By understanding these mechanisms, the research aims to identify potential therapeutic targets that could delay or prevent the onset of cognitive decline in humans.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for Alzheimer's disease, particularly those with metabolic dysfunction or early signs of cognitive decline.
Not a fit: Patients with advanced Alzheimer's disease or those who do not exhibit metabolic dysfunction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or delaying Alzheimer's disease and improving the quality of life for patients.
How similar studies have performed: Previous research has shown promising results in similar approaches targeting metabolic pathways to protect against neurodegenerative diseases, suggesting potential for success in this study.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Vatner, Stephen F — Rutgers Biomedical and Health Sciences
- Study coordinator: Vatner, Stephen F
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.